Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles

Biomaterials

Volumn 30, Issue 21, 2009, Pages 3614-3625

  Peng, Cheng Liang ^a   Lai, Ping Shan ^b   Lin, Feng Huei ^a   Yueh Hsiu Wu, Steven ^a   Shieh, Ming Jium ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Colon cancer; Micelle; Photodynamic therapy; SN 38; Star shaped copolymer

Indexed keywords

ANTI-TUMOR ACTIVITIES; CHLORIN; COLON CANCER; COMBINED EFFECTS; DELIVERY SYSTEMS; DUAL CARRIERS; DUAL THERAPIES; FUNCTIONALIZED; HUMAN COLON CANCERS; HYDRATION METHODS; HYDROPHOBIC DRUGS; MICROVESSEL DENSITIES; NANO-SIZED; RESIDENCE TIME; SELF-ASSEMBLE; SN-38; STAR BLOCK COPOLYMERS; STAR-SHAPED BLOCK COPOLYMERS; STAR-SHAPED COPOLYMER; SUBCUTANEOUS TUMORS; SYNERGISTIC COMBINATIONS; TUMOR ACCUMULATIONS; TUMOR GROWTHS;

BIOLOGICAL MATERIALS; BLOCK COPOLYMERS; CELL PROLIFERATION; CHEMOTHERAPY; COPOLYMERIZATION; MICELLES; ONCOLOGY; OPTICAL MATERIALS; PLASMONS; POLYMERS; TUMORS;

PHOTODYNAMIC THERAPY;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; COPOLYMER; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ENCAPSULATION; FEMALE; FREEZE DRYING; HUMAN; HUMAN CELL; HYDRATION; MICELLE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REGRESSION ANALYSIS; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICELLES; MOLECULAR STRUCTURE; PHOTOCHEMOTHERAPY; POLYMERS; PORPHYRINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67349112911     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.03.048     Document Type: Article

References (52)

1. Dolmans D., Fukumura D., and Jain R.K. Photodynamic therapy for cancer. Nat Rev Cancer 3 5 (2003) 380-387
2. Snyder J.W., Greco W.R., Bellnier D.A., Vaughan L., and Henderson B.W. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res 63 23 (2003) 8126-8131
3. Zhang G.D., Harada A., Nishiyama N., Jiang D.L., Koyama H., Aida T., et al. Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J Control Release 93 2 (2003) 141-150
4. Lai P.S., Lou P.J., Peng C.L., Pai C.L., Yen W.N., Huang M.Y., et al. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release 122 1 (2007) 39-46
5. Takeuchi Y., Ichikawa K., Yonezawa S., Kurohane K., Koishi T., Nango M., et al. Intracellular target for photo sensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome. J Control Release 97 2 (2004) 231-240
6. Vargas A., Pegaz B., Debefve E., Konan-Kouakou Y., Lange N., Ballini J.P., et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int J Pharm 286 1-2 (2004) 131-145
7. Ideta R., Tasaka F., Jang W.D., Nishiyama N., Zhang G.D., Harada A., et al. Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer. Nano Lett 5 12 (2005) 2426-2431
8. Jang W.D., Nakagishi Y., Nishiyama N., Kawauchi S., Morimoto Y., Kikuchi M., et al. Polyion complex micelles for photodynamic therapy: incorporation of dendritic photosensitizer excitable at long wavelength relevant to improved tissue-penetrating property. J Control Release 113 1 (2006) 73-79
9. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 5153 (1994) 1600-1603
10. Yasugi K., Nagasaki Y., Kato M., and Kataoka K. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(d,l-lactide) block copolymers as potential drug carrier. J Control Release 62 1-2 (1999) 89-100
11. Savic R., Luo L.B., Eisenberg A., and Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300 5619 (2003) 615-618
12. Kwon G.S., and Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 21 2 (1996) 107-116
13. Shuai X.T., Merdan T., Schaper A.K., Xi F., and Kissel T. Core-cross-linked polymeric micelles as paclitaxel carriers. Bioconjug Chem 15 3 (2004) 441-448
14. Torchilin V.P. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci 61 19-20 (2004) 2549-2559
15. Peng C.L., Shieh M.J., Tsai M.H., Chang C.C., and Lai P.S. Self-assembled star-shaped chlorine-core poly(ε-caprolactone)-poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies. Biomaterials 29 26 (2008) 3599-3608
16. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., Mcphail A.T., and Sim G.A. Plant antitumor agents. I. Isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca Acuminata. J Am Chem Soc 88 16 (1966) 3888-3890
17. Jaxel C., Kohn K.W., Wani M.C., Wall M.E., and Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase-I - evidence for a specific receptor-site and a relation to antitumor-activity. Cancer Res 49 6 (1989) 1465-1469
18. Rothenberg M.L. Topoisomerase I inhibitors: review and update. Ann Oncol 8 9 (1997) 837-855
19. Cunningham D., Pyrhonen S., James R.D., Punt C.J.A., Hickish T.F., Heikkila R., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1413-1418
20. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 13 (2000) 905-914
21. Noda W., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 2 (2002) 85-91
22. Negoro S., Masuda N., Takada Y., Sugiura T., Kudoh S., Katakami N., et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88 3 (2003) 335-341
23. Bodurka D.C., Levenback C., Wolf J.K., Gano J., Wharton J.T., Kavanagh J.J., et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21 2 (2003) 291-297
24. Rothenberg M.L., Kuhn J.G., Burris H.A., Nelson J., Eckardt J.R., Tristanmorales M., et al. Phase-I and pharmacokinetic trial of weekly Cpt-11. J Clin Oncol 11 11 (1993) 2194-2204
25. Rothenberg M.L., Kuhn J.G., Schaaf L.J., Rodriguez G.I., Eckhardt S.G., Villalona-Calero M.A., et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 12 11 (2001) 1631-1641
26. Maruyama K., Ishida O., Takizawa T., and Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 40 1-2 (1999) 89-102
27. Peng C.L., Lai P.S., and Shieh M.J. Influence of substitutions in asymmetric porphyrins on intracellular uptake, subcellular localization and phototoxicity in hela cells. Biomed Eng Appl Basis Commun 20 1 (2008) 9-17
28. Kim S.Y., Shin I.L.G., Lee Y.M., Cho C.S., and Sung Y.K. Methoxy poly(ethylene glycol) and epsilon-caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours. J Control Release 51 1 (1998) 13-22
29. Koizumi F., Kitagawa M., Negishi T., Onda T., Matsumoto S., Hamaguchi T., et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66 20 (2006) 10048-10056
30. Hwang R.F., Yokoi K., Bucana C.D., Tsan R., Killion J.J., Evans D.B., et al. Inhibition of platelet-derived growth factor receptor phosphorylation by ST1571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9 17 (2003) 6534-6544
31. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple-drugs or enzyme-inhibitors. Adv Enzyme Regul 22 (1984) 27-55
32. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 1-2 (2000) 271-284
33. Monsky W.L., Fukumura D., Gohongi T., Ancukiewcz M., Weich H.A., Torchilin V.P., et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59 16 (1999) 4129-4135
34. Litzinger D.C., Buiting A.M.J., Vanrooijen N., and Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochimica et biophysica acta 1190 1 (1994) 99-107
35. Zhang J.A., Xuan T., Parmar M., Ma L., Ugwu S., Ali S., et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 270 1-2 (2004) 93-107
36. Lai P.S., Pai C.L., Peng C.L., Shieh M.J., Berg K., and Lou P.J. Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J Biomed Mater Res Part A 87A 1 (2008) 147-155
37. Garcia-Carbonero R., and Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8 3 (2002) 641-661
38. O'Leary J., and Muggia F.M. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 34 10 (1998) 1500-1508
39. Opanasopit P., Yokoyama M., Watanabe M., Kawano K., Maitani Y., and Okano T. Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res 21 11 (2004) 2001-2008
40. Chiannilkulachai N., Ammoury N., Caillou B., Devissaguet J.P., and Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after iv administration in reticulosarcoma m-5076 metastasis-bearing mice. Cancer Chemother Pharmacol 26 2 (1990) 122-126
41. Morten I.J., Gosal W.S., Radford S.E., and Hewitt E.W. Investigation into the role of macrophages in the formation and degradation of beta(2)-microglobulin amyloid fibrils. J Biol Chem 282 40 (2007) 29691-29700
42. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53 2 (2001) 283-318
43. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54 5 (2002) 631-651
44. Shiah J.G., Sun Y.G., Peterson C.M., and Kopecek J. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release 61 1-2 (1999) 145-157
45. Nishiyama N., Nakagishi Y., Morimoto Y., Lai P.S., Miyazaki K., Urano K., et al. Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine. J Control Release 133 3 (2009) 245-251
46. Gomer C.J., Ferrario A., Luna M., Rucker N., and Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg Med 38 5 (2006) 516-521
47. Gollnick S.O., Evans S.S., Baumann H., Owczarczak B., Maier P., Vaughan L., et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 88 11 (2003) 1772-1779
48. Ferrario A., von Tiehl K.F., Rucker N., Schwarz M.A., Gill P.S., and Gomer C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60 15 (2000) 4066-4069
49. Ferrario A., Fisher A.M., Rucker N., and Gomer C.J. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 65 20 (2005) 9473-9478
50. Seshadri M., Spernyak J.A., Mazurchuk R., Camacho S.H., Oseroff A.R., Cheney R.T., et al. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res 11 11 (2005) 4241-4250
51. O'Leary J.J., Shapiro R.L., Ren C.J., Chuang N., Cohen H.W., and Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5 1 (1999) 181-187
52. Kamiyama H., Takano S., Tsuboi K., and Matsumura A. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1 alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131 4 (2005) 205-213